Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

59.86
+0.84001.42%
Post-market: 60.620.7600+1.27%19:30 EDT
Volume:2.67M
Turnover:160.22M
Market Cap:14.83B
PE:18.82
High:60.83
Open:59.00
Low:59.00
Close:59.02
52wk High:61.14
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:1.15
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:8.04
PE(LYR):21.53

Loading ...

Is Exelixis (EXEL) Undervalued On Cabozantinib Patent Risk And Launch Execution?

Simply Wall St.
·
Oct 10

Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says

MT Newswires Live
·
Oct 09

Exelixis is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Oct 09

Exelixis Inc : RBC Raises Target Price to $51 from $45

THOMSON REUTERS
·
Oct 09

RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating

MT Newswires Live
·
Oct 08

Exelixis price target raised to $54 from $52 at Truist

TIPRANKS
·
Oct 07

US Research Roundup-Allstate, Caribou Biosciences, Zscaler

Reuters
·
Oct 07

Exelixis Inc : Jefferies Raises Target Price to $70 from $66

THOMSON REUTERS
·
Oct 07

Exelixis Inc : Leerink Partners Assumes Coverage with Market Perform Rating; Target Price $55

THOMSON REUTERS
·
Oct 05

EXEL Industries Updates Share Capital and Voting Rights as of September 30, 2026

TIPRANKS
·
Oct 03

Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML)

TIPRANKS
·
Sep 14

Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed

TIPRANKS
·
Sep 14

FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating

TIPRANKS
·
Sep 13

Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)

TIPRANKS
·
Sep 13

Sector Update: Healthcare Stocks Ease in Afternoon Trading

MT Newswires Live
·
Sep 12

Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair

TIPRANKS
·
Sep 12

Analysts Offer Insights on NA Companies: Exelixis (EXEL) and HEICO (HEI)

TIPRANKS
·
Sep 11

Exelixis Shares Fall 3% After US FDA Extends Review of Co's Cancer Drug

THOMSON REUTERS
·
Sep 11

U.S. FDA Extends Review of Exelixis' Cancer Drug

Reuters
·
Sep 11

Exelixis - FDA Extends Review Period for Exelixis Nda for Zanzalintinib and Atezolizumab by Three Months - SEC Filing

THOMSON REUTERS
·
Sep 11